Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix
Abstract Equine influenza is a contagious disease caused by equine influenza virus which belongs to the orthomyxovirus family. Outbreaks of equine influenza cause severe economic loses to the horse industry and consequently horses in competition are required to be regularly vaccinated against equine...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2010-10, Vol.28 (43), p.6989-6996 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6996 |
|---|---|
| container_issue | 43 |
| container_start_page | 6989 |
| container_title | Vaccine |
| container_volume | 28 |
| creator | Heldens, J.G.M Pouwels, H.G.W Derks, C.G.G Van de Zande, S.M.A Hoeijmakers, M.J.H |
| description | Abstract Equine influenza is a contagious disease caused by equine influenza virus which belongs to the orthomyxovirus family. Outbreaks of equine influenza cause severe economic loses to the horse industry and consequently horses in competition are required to be regularly vaccinated against equine influenza. Unlike the existing inactivated vaccines, Equilis Prequenza Te is the only one able to induce protection against clinical disease and virus excretion after a primary vaccination course consisting of two vaccine applications 4–6 weeks apart until the recommended time of the third vaccination. In this paper we describe the duration of immunity profile, tested in an experimental setting according to European legislation, of this inactivated equine influenza and tetanus combination vaccine. In addition to influenza antigen, the formulation contains a second generation ISCOM (the so called ISCOMatrix) as an adjuvant. The vaccine aims at the induction of protection from the primary vaccination course until the time of annual revaccination 12 months later, against challenge with a virulent equine influenza strain. The protection against A/equine/Kentucky/95 (H3N8) at the time of annual revaccination was evidenced by a significant reduction of clinical signs of influenza, a significant reduction of virus excretion and a significant reduction of fever. The effect of the annual revaccination on the duration of immunity against influenza and tetanus was also studied by serology. For tetanus, as a consequence of the 24 months duration of immunity, an alternating annual vaccination schedule consisting of Prequenza and Prequenza Te is proposed after the first three doses of Prequenza Te. |
| doi_str_mv | 10.1016/j.vaccine.2010.08.043 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_757463974</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X10011886</els_id><sourcerecordid>757463974</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-572f021050e5a5116355da744e75c85012ffa94474ac11e3f44d11b70c1509943</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhiMEokvhJ4AiIVQuWWb8EScXEFq-KrXqoSBxs7yOI7wkTmvHWxbx43GUQKUe4GTp1TPveOadLHuKsEbA8tVuvVdaW2fWBJIG1RoYvZetsBK0IByr-9kKSMkKhvD1KHsUwg4AOMX6YXZEQJCKE7rKfr2LXo12cPnQ5rbvo7PjIbeuido0-faQK5eb65j6JLHtonE_VdKafDSjcjHkeui31s0Wy4_ydvB97GZNNbu4V25Mbjd2_JafXm4uzotzNXr743H2oFVdME-W9zj78uH9582n4uzi4-nm7VmhOcJYcEFaIAgcDFccsaScN0owZgTXFQckbatqxgRTGtHQlrEGcStAI4e6ZvQ4O5l9r_xwHU0YZW-DNl2nnBlikIILVtJaTOTLf5LJEIQoGdQJfX4H3Q3RuzSHRFYLQsqKT4Z8prQfQvCmlVfe9sofJIKcgpQ7uaxNTkFKqGQKMtU9W9zjtjfN36o_ySXgxQKooFXXeuW0DbccpQwZrxL3ZuZMWvDeGi-DtsaldK03epTNYP_7ldd3HHRnnU1Nv5uDCbdTy0AkyMvp6qajQwDEqirpbz-F0nk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1497226854</pqid></control><display><type>article</type><title>Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Heldens, J.G.M ; Pouwels, H.G.W ; Derks, C.G.G ; Van de Zande, S.M.A ; Hoeijmakers, M.J.H</creator><creatorcontrib>Heldens, J.G.M ; Pouwels, H.G.W ; Derks, C.G.G ; Van de Zande, S.M.A ; Hoeijmakers, M.J.H</creatorcontrib><description>Abstract Equine influenza is a contagious disease caused by equine influenza virus which belongs to the orthomyxovirus family. Outbreaks of equine influenza cause severe economic loses to the horse industry and consequently horses in competition are required to be regularly vaccinated against equine influenza. Unlike the existing inactivated vaccines, Equilis Prequenza Te is the only one able to induce protection against clinical disease and virus excretion after a primary vaccination course consisting of two vaccine applications 4–6 weeks apart until the recommended time of the third vaccination. In this paper we describe the duration of immunity profile, tested in an experimental setting according to European legislation, of this inactivated equine influenza and tetanus combination vaccine. In addition to influenza antigen, the formulation contains a second generation ISCOM (the so called ISCOMatrix) as an adjuvant. The vaccine aims at the induction of protection from the primary vaccination course until the time of annual revaccination 12 months later, against challenge with a virulent equine influenza strain. The protection against A/equine/Kentucky/95 (H3N8) at the time of annual revaccination was evidenced by a significant reduction of clinical signs of influenza, a significant reduction of virus excretion and a significant reduction of fever. The effect of the annual revaccination on the duration of immunity against influenza and tetanus was also studied by serology. For tetanus, as a consequence of the 24 months duration of immunity, an alternating annual vaccination schedule consisting of Prequenza and Prequenza Te is proposed after the first three doses of Prequenza Te.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2010.08.043</identifier><identifier>PMID: 20728523</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Adjuvants, Immunologic - pharmacology ; Allergy and Immunology ; Animals ; Antibodies, Viral - blood ; Applied microbiology ; Biological and medical sciences ; Challenge ; Duration of immunity ; Equine influenza ; Equine influenza virus ; Excretion ; Fundamental and applied biological sciences. Psychology ; Horse Diseases - immunology ; Horse Diseases - prevention & control ; Horses ; Horses - immunology ; Influenza ; Influenza A Virus, H3N8 Subtype - immunology ; Influenza Vaccines - immunology ; ISCOM-Matrix ; ISCOMs - immunology ; Legislation ; Microbiology ; Orthomyxoviridae Infections - immunology ; Orthomyxoviridae Infections - prevention & control ; Orthomyxoviridae Infections - veterinary ; Orthomyxovirus ; Studies ; Tetanus ; Tetanus - immunology ; Tetanus - prevention & control ; Tetanus - veterinary ; Tetanus Toxoid - immunology ; Vaccination - veterinary ; Vaccination schedule ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Combined - immunology</subject><ispartof>Vaccine, 2010-10, Vol.28 (43), p.6989-6996</ispartof><rights>Elsevier Ltd</rights><rights>2010 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Oct 8, 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-572f021050e5a5116355da744e75c85012ffa94474ac11e3f44d11b70c1509943</citedby><cites>FETCH-LOGICAL-c510t-572f021050e5a5116355da744e75c85012ffa94474ac11e3f44d11b70c1509943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X10011886$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23341458$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20728523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Heldens, J.G.M</creatorcontrib><creatorcontrib>Pouwels, H.G.W</creatorcontrib><creatorcontrib>Derks, C.G.G</creatorcontrib><creatorcontrib>Van de Zande, S.M.A</creatorcontrib><creatorcontrib>Hoeijmakers, M.J.H</creatorcontrib><title>Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Equine influenza is a contagious disease caused by equine influenza virus which belongs to the orthomyxovirus family. Outbreaks of equine influenza cause severe economic loses to the horse industry and consequently horses in competition are required to be regularly vaccinated against equine influenza. Unlike the existing inactivated vaccines, Equilis Prequenza Te is the only one able to induce protection against clinical disease and virus excretion after a primary vaccination course consisting of two vaccine applications 4–6 weeks apart until the recommended time of the third vaccination. In this paper we describe the duration of immunity profile, tested in an experimental setting according to European legislation, of this inactivated equine influenza and tetanus combination vaccine. In addition to influenza antigen, the formulation contains a second generation ISCOM (the so called ISCOMatrix) as an adjuvant. The vaccine aims at the induction of protection from the primary vaccination course until the time of annual revaccination 12 months later, against challenge with a virulent equine influenza strain. The protection against A/equine/Kentucky/95 (H3N8) at the time of annual revaccination was evidenced by a significant reduction of clinical signs of influenza, a significant reduction of virus excretion and a significant reduction of fever. The effect of the annual revaccination on the duration of immunity against influenza and tetanus was also studied by serology. For tetanus, as a consequence of the 24 months duration of immunity, an alternating annual vaccination schedule consisting of Prequenza and Prequenza Te is proposed after the first three doses of Prequenza Te.</description><subject>Adjuvants, Immunologic - pharmacology</subject><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antibodies, Viral - blood</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Challenge</subject><subject>Duration of immunity</subject><subject>Equine influenza</subject><subject>Equine influenza virus</subject><subject>Excretion</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Horse Diseases - immunology</subject><subject>Horse Diseases - prevention & control</subject><subject>Horses</subject><subject>Horses - immunology</subject><subject>Influenza</subject><subject>Influenza A Virus, H3N8 Subtype - immunology</subject><subject>Influenza Vaccines - immunology</subject><subject>ISCOM-Matrix</subject><subject>ISCOMs - immunology</subject><subject>Legislation</subject><subject>Microbiology</subject><subject>Orthomyxoviridae Infections - immunology</subject><subject>Orthomyxoviridae Infections - prevention & control</subject><subject>Orthomyxoviridae Infections - veterinary</subject><subject>Orthomyxovirus</subject><subject>Studies</subject><subject>Tetanus</subject><subject>Tetanus - immunology</subject><subject>Tetanus - prevention & control</subject><subject>Tetanus - veterinary</subject><subject>Tetanus Toxoid - immunology</subject><subject>Vaccination - veterinary</subject><subject>Vaccination schedule</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Combined - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1v1DAQhiMEokvhJ4AiIVQuWWb8EScXEFq-KrXqoSBxs7yOI7wkTmvHWxbx43GUQKUe4GTp1TPveOadLHuKsEbA8tVuvVdaW2fWBJIG1RoYvZetsBK0IByr-9kKSMkKhvD1KHsUwg4AOMX6YXZEQJCKE7rKfr2LXo12cPnQ5rbvo7PjIbeuido0-faQK5eb65j6JLHtonE_VdKafDSjcjHkeui31s0Wy4_ydvB97GZNNbu4V25Mbjd2_JafXm4uzotzNXr743H2oFVdME-W9zj78uH9582n4uzi4-nm7VmhOcJYcEFaIAgcDFccsaScN0owZgTXFQckbatqxgRTGtHQlrEGcStAI4e6ZvQ4O5l9r_xwHU0YZW-DNl2nnBlikIILVtJaTOTLf5LJEIQoGdQJfX4H3Q3RuzSHRFYLQsqKT4Z8prQfQvCmlVfe9sofJIKcgpQ7uaxNTkFKqGQKMtU9W9zjtjfN36o_ySXgxQKooFXXeuW0DbccpQwZrxL3ZuZMWvDeGi-DtsaldK03epTNYP_7ldd3HHRnnU1Nv5uDCbdTy0AkyMvp6qajQwDEqirpbz-F0nk</recordid><startdate>20101008</startdate><enddate>20101008</enddate><creator>Heldens, J.G.M</creator><creator>Pouwels, H.G.W</creator><creator>Derks, C.G.G</creator><creator>Van de Zande, S.M.A</creator><creator>Hoeijmakers, M.J.H</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7U2</scope><scope>7X8</scope></search><sort><creationdate>20101008</creationdate><title>Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix</title><author>Heldens, J.G.M ; Pouwels, H.G.W ; Derks, C.G.G ; Van de Zande, S.M.A ; Hoeijmakers, M.J.H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-572f021050e5a5116355da744e75c85012ffa94474ac11e3f44d11b70c1509943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adjuvants, Immunologic - pharmacology</topic><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antibodies, Viral - blood</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Challenge</topic><topic>Duration of immunity</topic><topic>Equine influenza</topic><topic>Equine influenza virus</topic><topic>Excretion</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Horse Diseases - immunology</topic><topic>Horse Diseases - prevention & control</topic><topic>Horses</topic><topic>Horses - immunology</topic><topic>Influenza</topic><topic>Influenza A Virus, H3N8 Subtype - immunology</topic><topic>Influenza Vaccines - immunology</topic><topic>ISCOM-Matrix</topic><topic>ISCOMs - immunology</topic><topic>Legislation</topic><topic>Microbiology</topic><topic>Orthomyxoviridae Infections - immunology</topic><topic>Orthomyxoviridae Infections - prevention & control</topic><topic>Orthomyxoviridae Infections - veterinary</topic><topic>Orthomyxovirus</topic><topic>Studies</topic><topic>Tetanus</topic><topic>Tetanus - immunology</topic><topic>Tetanus - prevention & control</topic><topic>Tetanus - veterinary</topic><topic>Tetanus Toxoid - immunology</topic><topic>Vaccination - veterinary</topic><topic>Vaccination schedule</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Combined - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heldens, J.G.M</creatorcontrib><creatorcontrib>Pouwels, H.G.W</creatorcontrib><creatorcontrib>Derks, C.G.G</creatorcontrib><creatorcontrib>Van de Zande, S.M.A</creatorcontrib><creatorcontrib>Hoeijmakers, M.J.H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Safety Science and Risk</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heldens, J.G.M</au><au>Pouwels, H.G.W</au><au>Derks, C.G.G</au><au>Van de Zande, S.M.A</au><au>Hoeijmakers, M.J.H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2010-10-08</date><risdate>2010</risdate><volume>28</volume><issue>43</issue><spage>6989</spage><epage>6996</epage><pages>6989-6996</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract Equine influenza is a contagious disease caused by equine influenza virus which belongs to the orthomyxovirus family. Outbreaks of equine influenza cause severe economic loses to the horse industry and consequently horses in competition are required to be regularly vaccinated against equine influenza. Unlike the existing inactivated vaccines, Equilis Prequenza Te is the only one able to induce protection against clinical disease and virus excretion after a primary vaccination course consisting of two vaccine applications 4–6 weeks apart until the recommended time of the third vaccination. In this paper we describe the duration of immunity profile, tested in an experimental setting according to European legislation, of this inactivated equine influenza and tetanus combination vaccine. In addition to influenza antigen, the formulation contains a second generation ISCOM (the so called ISCOMatrix) as an adjuvant. The vaccine aims at the induction of protection from the primary vaccination course until the time of annual revaccination 12 months later, against challenge with a virulent equine influenza strain. The protection against A/equine/Kentucky/95 (H3N8) at the time of annual revaccination was evidenced by a significant reduction of clinical signs of influenza, a significant reduction of virus excretion and a significant reduction of fever. The effect of the annual revaccination on the duration of immunity against influenza and tetanus was also studied by serology. For tetanus, as a consequence of the 24 months duration of immunity, an alternating annual vaccination schedule consisting of Prequenza and Prequenza Te is proposed after the first three doses of Prequenza Te.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>20728523</pmid><doi>10.1016/j.vaccine.2010.08.043</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2010-10, Vol.28 (43), p.6989-6996 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_757463974 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adjuvants, Immunologic - pharmacology Allergy and Immunology Animals Antibodies, Viral - blood Applied microbiology Biological and medical sciences Challenge Duration of immunity Equine influenza Equine influenza virus Excretion Fundamental and applied biological sciences. Psychology Horse Diseases - immunology Horse Diseases - prevention & control Horses Horses - immunology Influenza Influenza A Virus, H3N8 Subtype - immunology Influenza Vaccines - immunology ISCOM-Matrix ISCOMs - immunology Legislation Microbiology Orthomyxoviridae Infections - immunology Orthomyxoviridae Infections - prevention & control Orthomyxoviridae Infections - veterinary Orthomyxovirus Studies Tetanus Tetanus - immunology Tetanus - prevention & control Tetanus - veterinary Tetanus Toxoid - immunology Vaccination - veterinary Vaccination schedule Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Combined - immunology |
| title | Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T10%3A56%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Duration%20of%20immunity%20induced%20by%20an%20equine%20influenza%20and%20tetanus%20combination%20vaccine%20formulation%20adjuvanted%20with%20ISCOM-Matrix&rft.jtitle=Vaccine&rft.au=Heldens,%20J.G.M&rft.date=2010-10-08&rft.volume=28&rft.issue=43&rft.spage=6989&rft.epage=6996&rft.pages=6989-6996&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2010.08.043&rft_dat=%3Cproquest_cross%3E757463974%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1497226854&rft_id=info:pmid/20728523&rft_els_id=S0264410X10011886&rfr_iscdi=true |